°Q½×°Ï>¤ß®®¥ÍÂå
Åý§Ú­Ì¤@°_¬°¤ß®®¥ÍÂå¼g¤é°O
·|­û:²q·Q 10136148 µoªí®É¶¡:2017/8/21 ¤U¤È 05:20:28
§N¼ö´`Àô , ¬O¥|©uªº¥²µM

º¦¶^¥æ´À , ¬OªÑ¥«ªº°¸µM

¶}³o­Óª©¤D¦³·P©ó

Cliff¤j®¦¼w¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡zªº±M·~½×­z

Åý¤p§Ìµo¨¥®É , ²`©È·\¹ï¤j®aªºµ§°O

¤]©È§j½K¤@´ò¬K¤ô , ¯}Ãa¤j®aªY½à±M·~ªº¬ü·P

©Ò¥H , ³o­Óª©

¤£¥u 543 ¥i¥H½Í 1234567890abcdef ¤]Åwªï

§Æ±æ¼ö¾x¬O­ì«h

¥»ª©¬O¦h¨¥°ó ¦h¤è¬Ý¨Æ ¦h±¡¹ï«Ý

¬ß±æ

¡y¤ß®®¥ÍÂå²£«~½u»PÄvª§¹ï¤â¡z¬O§Ú­Ìªº¦@¦Pµ§°O

¡yÅý§Ú­Ì¤@°_¬°¤ß®®¥ÍÂå¼g¤é°O¡z«h¬OÄÝ©ó¤j®aªº¦@¦P¤é°O

´Á«Ý±zªº°Ñ»P

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/11 ¤U¤È 12:23:44²Ä873½g¦^À³
Æ[ÂI

¬°¤°»ò¯«¸g¬ì§Þ±N¦¨¬°21¥@¬öªº²^ª÷¼ö¼é

¨Ó·½¡G¤õ¥Û³Ð³y ¡@2018-06-11

§@ªÌ¡GBeth Rosellini

ĶªÌ¡G»¯¦¨Às

¦ÑÄ֤ƪº§x¹Ò

¤£¥i§_»{ªº¬O¡A¯«¸g¬ì§Þ¦]¬°600¾lºØ¯«¸g¨t²Î¯e¯fªº¦s¦b¦Ó±N¦b¥þ²y½d³ò¤º¾Ö¦³¥¨¤jªº¼ç¦b¥«³õ¡CRoger Dooleyªº²Î­p¼Æ¾ÚºÙ¡A¥þ²y¦³¥|¤À¤§¤@ªº¤H±w¦³»P¸£¬ÛÃöªº¯e¯f¡A¨Ã¥BÀHµÛ¦ÑÄ֤ƶiµ{ªº¥[¼@¡A³o¤@¤ñ¨ÒÁÙ±N¶i¤@¨B¤W¤É¡C¥@¬É¸gÀٽ׾¬Ʀܦô­p¡A¶W¹L80·³ªº¤H¸s¤¤±N¦³¤T¤À¤§¤@·|¥Ñ©ó¦Ñ¦~è§b¯g¦Ó¥¢¯à¡A¨Ã¥B«ü¥X¥¼¨Ó¯«¸g¬ì§Þªº¬ã¨s©Mµo®i±N¬O«D±`­¢¤Áªº»Ý¨D¡C

¾¨ºÞ³o¨Ç¯e¯f«D±`²±¦æ¡A¦ý¬O¥Ø«e¹ï¨äÁ{§ÉªvÀø¹ê½î¤´µM¨ã¦³¬D¾Ô©Ê¡C§Ú¹ï³o¨Ç±wªÌ¡]¥]¬A©¬ª÷´Ë¯f±wªÌ¡^ªº¬ã¨sµo²{¡A¾¨ºÞ60·³¥H¤W±w¦³¯«¸g¨t²Î¯e¯f»´«×¯gª¬ªº±wªÌ¤H¼Æ²³¦h¡A¦ý¬O¥Ñ©óªì¶EÂå¥Í¬°¥L­ÌÀˬdªº®É¶¡«Üµu¡A¦]¦¹¤j³¡¤À±wªÌ¤£·|±µ¨ü¥þ­±ªº¯«¸gÀˬd¡C¨Æ¹ê¤W¡A¤j¦h¼Æ±wªÌ¥u¦³¦bµo¥Í¨®º×©ÎªÌ¾É­P°©ÀYÂ_µõªº­«¤j¼Y¸¨¨Æ¬G®É¤~·|³Q¶EÂ_¥X¨Ó¡C

³o¤@°ÝÃD¤]»·»·¤£¬O¶EÂ_¨º»ò²³æ¤F¡A±wªÌ¦b³Q¶EÂ_¥X¨Ó¤§«á¡A¨äªvÀø©MÂà¶E¹Lµ{¤]·|¥Rº¡¥¢»~©M»Ùê¡C¥Ø«e¤w¦³ªºÃĪ«±a¦³¤@¨t¦Cªº°Æ§@¥Î¡A¹ï±wªÌªº¥Í¬¡½è¶q·|³y¦¨­«¤j¼vÅT¡C¨Ò¦p¡A§Úªº¬ã¨sµo²{¤j¦h¼Æ65·³¥H¤Wªº±wªÌ¨C¤Ñ»Ý­nªA¥Î¤CºØÃĪ«¡C

³o¨Çµo²{¥i´d¦aªí©ú¡A¥Ñ©ó¶EÂ_ªº©µ»~¡B¥i¿ï¾ÜªvÀø¤â¬qªº¯Ê¥F©M¥O¤H¤£§ÖªºÃĪ«ªvÀø¡A§Ú­Ì¥Ø«e¹ï¯«¸g¯e¯fªººÞ²zÄY­«¤£¨¬¡CµM¦Ó¡A¬ã¨sµ²ªG¤]«ü¥X¡A¯«¸g¬ì§Þ¥«³õªºµo®i¤w¸g¦¨¼ô¡A¨Ã¬°¸Ñ¨M¥Ø«e§Ú­ÌªºªÀ·|©Ò­±Á{ªº¤@¨Ç­«¤j°·±d°ÝÃD´£¨Ñ¤F¼ç¤O¡C

ÀHµÛ¹ï¸Ñ¨M¤è®×ªº»Ý¨D¤£Â_¼W¥[¥H¤Î¤£Â_¨ú±oªº¶i®i¡A¯«¸g¬ì§Þ­²©R±N·|¦³§ó¦hªº¸êª÷©M·P¿³½ìªÌ´é¤J¡C¦]¦¹¡A»¡¯«¸g¬ì§Þ±N¦¨¬°21¥@¬öªº²^ª÷¼ö²@¤£¬°¹L¡C

·|­û:booli10146418µoªí®É¶¡:2018/6/11 ¤W¤È 08:23:42²Ä872½g¦^À³
¥@¬É¶V§Ö¡A¤ß¶V±YÃa

¤ß®®¦¨¥\¡A¤ß¶V´r§Ö

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/10 ¤U¤È 11:23:07²Ä871½g¦^À³
liaw6575¤j¤j§ï¤F¼ÐÃD©M³¡¤À¤º®e

¼ÐÃD§ï¬°¡G

¥@¬É¶V§Ö ¤ß¶VºC?

¤º®e§ó¬°¡G

­YSNG-12¦¨¥\ ,±N¥i¥H¦¨¬°¥þ¥@¬É²Ä¤@´Ú¤fªAªº¦Û±þ¨¾ªvÃĪ« ,±N¬O¯uªº±Ï¤H¤@©Rªº·sÃÄ

ÁÂÁ¤j®a¡I

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/10 ¤U¤È 07:56:59²Ä870½g¦^À³

liaw6575¤j¤j¹ï¦Û±þªº²Î­p¸ê®Æ¤À¨É

¥@¬É¶V§Ö ¤ß®®ºC?

liawbf.pixnet.net/blog/post/47974122

¦P¬O¥LÁ|¥xÆW¦Û±þ¨¾ªv¾Ç·|2015ªº¾ã²z¸ê®Æ

¥þ²y¤H¤f¤¤¬ù¦³ 9% ªº¤H¤@¥Í¤¤¦Ü¤Ö¥X²{¤@¦¸¦Û±þ·N©À

¤@­Ó¸ó¶V17°ê½Õ¬d84850¤Hªº¶W¤j³W¼Ò¬ã¨s

µo²{¦UÃþ«¬²×¥Í²±¦æ²v,¥]¬A¦Û±þ·N©À 9.2% ,¦Û±þ­pµe 3.1% ,¦Û±þ¥ø¹Ï 2.7% ...

¦AªÌ

¦³¦Û±þ·N©ÀªÌªº25%¤ñ¨Ò ,·|²£¥Í¦Û±þ¥ø¹Ï;¦Û±þ·N©ÀªÌªº5%¤ñ¨Ò ,·|¦Û±þ§¹¦¨

¦]¦¹ ,¨¾ªv¦Û±þ·N©À ,´N¬O¦b¹w¨¾¦Û±þ

liaw6575¤j¤jµ²½×¹D

­YSNG-12¦¨¥\ ,±N¥i¥H¦¨¬°¥þ¥@¬É²Ä¤@´Ú¦Û±þ¨¾ªvÃĪ« ,±N¬O¯uªº±Ï¤H¤@©Rªº·sÃÄ

ÁÂÁÂliaw6575¤j¤jªº¤À¨É

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/10 ¤U¤È 05:22:42²Ä869½g¦^À³
§Ú­Ì¯à§_¬°SNG-12 §ä­Ó¾AÀ³¯gªº²z·Q¦ì¤l ?

¬Ý¬Ý¦bÆ{§í¯g»â°ìªºBTD , ¾AÀ³¯g¦U¦³¤£¦P

esketamine : ( ÀR¯ß ? ©Î »ó¤ºµ¹ÃÄ )

2013/11

for treatment-resistant depression

2016/08

The designation was granted for major depressive disorder with imminent risk for suicide.(ÄY­«§íÆ{¯g¨Ã¦³§Y±Nµo¥Íªº¦Û±þ­·ÀI)

Rapastinel : ( NMDA receptor partial agonist ) ÀR¯ßµ¹ÃÄ

2016/01

for Adjunctive Treatment of Major Depressive Disorder (MDD)

SAGE-547 : ( GABA modulator ) ÀR¯ßµ¹ÃÄ

2016/09

ªvÀø²£«á§íÆ{¯g¡]PPD¡^

SAGE-217 : ( GABA modulator ) ¤fªA

2018/02

for the treatment of major depressive disorder (MDD)

©Ò¥H SNG-12 ­nÂ\¦b­þ¸Ì©O?

³o¼Ë¦n¶Ü?

for major depressive disorder with suicidal ideation ?

²¦³º¶W¹L940¸Uªº¬ü°ê¤H¦³ÄY­«ªº¦Û±þ«äºû , À³¸Ó¦³¥«³õ¤~¹ï

­J«ä¶Ã·Q¤§Á|

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/10 ¤W¤È 11:44:48²Ä868½g¦^À³
¸ô³zªÀªº·s»D

¬ü°ê¦Û±þ¼éªº¿³°_¥YÅã¤F·s«¬§íÆ{¯gÃĪ«ªº»Ý¨D

2018¦~6¤ë9¤é/ 4:30 AM / 8¤p®É«e§ó·s

Julie Steenhuysen

ªÛ¥[­ô¡]¸ô³zªÀ¡^ - ¬ü°ê¦Û±þ²v¤j´T¤W¤É¡A¥O¤H·NÃѨì»Ý­n§ó¦³®Ä¦aªvÀø­««×§íÆ{¯g¡A¬ã¨s¤H­ûºÙ³o¬O¤@­Ó´Æ¤âªºµo®i»â°ì¡A¤j³¡¤À»sÃĤ½¥q¤w¸g©ñ±ó¤F³o¤@»â°ì¡C

¬ü°ê½Ã¥Í·í§½¶g¥|ªí¥Ü¡A¦Û¥»¥@¬öªì¥H¨Ó¡A¥þ°ê¦U¦aªº¦Û±þ²v«æ¼@¤W¤É¡A¨Ã©IÆ~±Ä¨úºî¦X±¹¬I¸Ñ¨M§íÆ{¯g°ÝÃD¡C¸Ó³ø§i¦b¦P¤@©Pµo¥¬¡A§@¬°¦W¤H Anthony Bourdain ©M Kate Spade ªº°ª½Õ¦Û±þ¡C

¸ô³zªÀµLªk½T©wBourdain©ÎSpade¬O§_¥¿¦b±µ¨üÃĪ«ªvÀø¡C

®Ú¾Ú¬ü°êÃÄ«~¬ã¨s»P»s³y°Ó¨ó·|ªº³ø§i¡A»sÃĤ½¥q¥¿¦b¶}µo°w¹ïºë¯«°·±d°ÝÃDªº140ºØÀøªk¡A¨ä¤¤39ºØ°w¹ï§íÆ{¯g¡C³o»P¸Ó¦æ·~¦b1100ºØ¹êÅç©ÊÀù¯gÃĪ«¤è­±ªº¤u§@¬Û¤ñ¡A³o¨ÇÃĪ«¥i¥H±±¨î¤@¨Ç³Ì°ªªº»ù®æ¡C

...

¨ä¤¤¤å¤º´£°_ªº´XÀÉÁ{§É¤¤ÃĪ« , ³£¬O§Ú­Ì¦Õ¼ô¯à¸ÔÀò±oBTDºa»Îªº·sÃÄ

J&J¡¦s esketamine

SAGE ªº SAGE-547 , 217

Allergan Plc ªº rapastinel ( GLYX-13 )

¦Ñ¥v¤j¤j

liaw6575¤j¤j

ÁÙ¦³´²¥¬¦b¥²´Iºôªº¨ä¥L¤j¤j¤å³¹

³£¦³±´°Q

¥i±¤¦Ñ¥v¤j¤jªººô­¶ ¤p§Ì¥´¤£¶}

liaw6575¤j¤j ½Ð°Ñ

liawbf.pixnet.net/blog/category/2056471

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/7 ¤U¤È 09:11:16²Ä867½g¦^À³
SNG-12ªº¨ä¤¤¤@¶µ¾AÀ³¯g¬O¦Û±þ¯gª¬

µM¦Ó¦³³oºØ¦Û±þ·N©Àªº±wªÌ¦h¤£¦h©O¡H

®Ú¾Ú .mentalhealth.gov ºô¯¸ªº¸ê®Æ

On average, 122 Americans die by suicide each day. Suicide is the second leading cause of death among 15-24 year olds and more than 9.4 million adults in the United States had serious thoughts of suicide within the past 12 months.

¦b¬ü°ê¡A¹L¥h12­Ó¤ë 940 ¸U¤H¦³ÄY­«ªº¦Û±þ«äºû

¯u¬O¶W¥G¤pªº·Q¹³

­ì¨Ó¦³³o»ò¦h¤H³B¦bÄY­«¦Û±þ«äºûªº±¡¹Ò¤¤

Ä@Ãļt¬ãµo·sÃÄ¥H¸Ñ²³¦h±wªÌªºµh­W©M»Ý¨D

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a¡I

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/7 ¤U¤È 01:03:29²Ä866½g¦^À³
Axovant Sciences«Å¥¬Àò±o©¬ª÷´Ë¯f°ò¦]Àøªk¿W®a±ÂÅv

¨Ó·½¡GÃÄ©ú±d¼w¡@2018-06-07

med.sina.com/article_detail_100_2_47080.html

¤µ¤é¡A Axovant Sciences «Å¥¬¤w±qOxford BioMedica Àò±o¥þ²y¿W®a±ÂÅv¡A¶}µo¨Ã±À¼s©¬ª÷´Ë¯f°ò¦]ÀøªkAXO-Lenti-PD ¡]´¿¥Î¦WOXB-102 ¡^¡CAxovant ¹w­p±N©ó¤µ¦~©³¶}©l¹ï±ß´Á©¬ª÷´Ë¯f±wªÌ¶i¦æAXO-Lenti-PD ªº1/2 ´Á¾¯¶q»¼¼W¬ã¨s¡C

AXO-Lenti-PD §@¬°¤U¤@¥N°ò¦]Àøªk¡A¬°©¬ª÷´Ë¯fªºªvÀø±a¨Ó·sªº¥i¯à¡COxford BioMedica ¤w¸g¦¨¥\§¹¦¨ProSavin® ªº1/2 ´Á¬ã¨s¡A¨Ã©è¹F¥D­n²×ÂI¡C¨äµ²ªGªí©ú¡A¦b6 ­Ó¤ë©M12 ­Ó¤ë®É¡A³q¹LUPDRS ²ÄIII ³¡¤Àµû¤À´ú¶q¡A¸ÓÃĪ«ÃÒ©ú¤F¨ä¦w¥þ©Ê©M­@¨ü©Ê¡A¥H¤Î¹ï¹B°Ê¥\¯àªºÅãµÛ§ïµ½¡CÁöµM©¬ª÷´Ë¯f·|¾É­P³vº¥°h¤Æ¡A¦ý¸ÓÃĪ«µ¹¤j¦h¼Æ±wªÌ±a¨Óªº§ïµ½¥i«ùÄò¹F¥|¦~¡C

®Ú¾Ú»P Oxford BioMedica ñ­qªº³\¥i¨óij±ø´Ú¡AAxovant ±N­º¥ý¤ä¥I 3000 ¸U¬ü¤¸¡A¥HÀò±oAXO-Lenti-PD ¤Î¨ä«e¨­²£«~ProSavin® ªºÅv§Q¡C

¦pªG¸ÓÃĪ«Àò±o§å­ã¡AOxford BioMedica ÁÙ¦³¸ê®æÃB¥~Àò±o¶W¹L 8.12 »õ¬ü¤¸ªº¶}µo¡BºÊºÞ©M±À¼s¨½µ{¸O¶O¥Î¡A¥H¤ÎAXO-Lenti-PD ªº²b¾P°âÃB¯S³\Åv¨Ï¥Î¶O¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/7 ¤U¤È 12:09:09²Ä865½g¦^À³
«äı¥¢½Õ¯g¥iÂåªv ¤Î¦­µo²{´_­ì®ÄªG¦n

2018-06-07 11:55¤¤¥¡ªÀ «n§ë7¤é¹q

udn.com/news/story/7266/3185057?from=udn_ch1cate6649_pulldownmenu

³¯«í¥Íªí¥Ü¡A«äı¥¢½Õ¯gªº²±¦æ²v¬ù¬°3/1000¡A¦pªG¤Î¦­µo²{¡A¤Î¦­ªvÀø¡A¥ÎÃÄ´_­ìªºª¬ªp·|§ó¦n¡A¦P®É¨¾¤î¸£³¡·l¶Ë¡A¥u­n¦bµo¯f¤@¦~¤º´NÂå¡A¤j¬ù¥i¥H«ì´_7¦¨¥H¤Wªº¸£³¡¥\¯à¡A¤£¹L¥ÎÃĤ£¯à¶¡Â_¡A¦]¬°´¿¦³¬ã¨s«ü¥X¡A§Y¨Ï¤¤Â_¥ÎÃĮɶ¡¤£¨ì10¤Ñ¡A¯gª¬´_µo¥B»Ý­n¦í°|ªº­·ÀI«o°ª¹F2­¿¥H¤W¡C

³¯«í¥Í»¡¡A«äı¥¢½Õ¯g¦pªG¤£¿n·¥ªvÀø¡A·|´c¤Æ¨ìµLªk¦Û§Ú·ÓÅUªºµ{«×¡A¯fÃÑ·P¤]·|ÀHµÛ¯e¯f´c¤Æ¦Ó®ø¥¢¡A¯f±w¦bµo¯fªì´ÁÁÙª¾¹D¦Û¤v»P¥¿±`¤H¦³ÂI¤£¤@¼Ë¡A¤£¹LÀHµÛ¯fµoÀW²vªº¼W¥[¡A¯f±w·|¶}©l¥D°Ê¸ÑÄÀ¦Û¤vªº·P¨ü¦Ó³vº¥§Î¦¨©TµÛªº·Qªk¡A¦P®É³vº¥¥¢¥h¯fÃÑ·P¡C

³¯«í¥Íªí¥Ü¡A¯f±w¦pªG¤Î¦­¥B¿n·¥ªvÀø¡A³Ì¦nªºª¬ªp¤´µM¯à°÷©M¥¿±`¤H¤@¼Ëªº¥Í¬¡¡Aºû«ù­ì¥»ªºªÀ·|¾·~¥\¯à¡A¤£¹L«äı¥¢½Õ¯g¤£ºÞ¹ï¯f±w¡B®a¤H¥H¤ÎªÀ·|¨Ó»¡³£¬Oªø´Á§Ü¾Ô¡A°ß¦³¦U¤è­±«O«ù¦X§@¡A¤~¯à¹F¨ì³Ì¦nªºªvÀø®ÄªG¡C

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/5 ¤W¤È 08:31:59²Ä864½g¦^À³
¥¢´¼¯g5¦~¼W1% ·ÓÅ@°ÝÃD³ô¼~

2018-06-05

news.ltn.com.tw/news/focus/paper/1206423

.¥h¦~27¸U¤H¥¢´¼ ²±¦æ²v¬ù8¢H

.¥¼¨Ó45¦~ ®£¤é¼W36¦W¥¢´¼±wªÌ

.¶W¹L5¦¨±wªÌ ¥Ñ®a¤Hªø´Á·ÓÅU

·ÓÅ@°ÝÃD³ô¼~¡I¥¼¨Ó45¦~®£¤é¼W36¦W¥¢´¼±wªÌ

2018-06-05 07:32

news.ltn.com.tw/news/life/breakingnews/2447805

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/4 ¤U¤È 03:59:57²Ä863½g¦^À³
ù¤ó²×¤î¨u¨£¯f·sÃĶ}µo¡G§xÃø¤Ó¦h

¨Ó·½¡G°·ÂI¤lihealth¡@2018-06-04

med.sina.com/article_detail_100_2_46867.html

ù¤ó¡]Roche¡^¥¿¦¡«Å¥¬¡A²×¤î3¦~«e§ë¸ê1.2»õ¬ü¤¸±qTrophos¤½¥q¦¬ÁʪºolesoximeªvÀøSMA2«¬ªºÁ{§É¸ÕÅç¡C

SMA¬O¤@ºØÄY­«ªº¯«¸g¦Ù¦×¯e¯f¡A¯gª¬¬O¹B°Ê¯«¸g¤¸ªº³à¥¢¡A¾É­P¶i¦æ©Ê¦ÙµL¤O©MÅõºÈ¡C

»P¦¹¦P®É¡A·s¿³ªº°ò¦]ªvÀø¤è¿³¥¼¦ã¡CAveXis¤½¥qªº¥D¥´²£«~AVXS-101¡A §Q¥Î¸¢¬ÛÃö¯f¬r¸üÅé¡]AAV¡^§Þ³N¡A±NSMN1°ò¦]ª½±µ¹B°e¨ìÅ餺¡A´Á±æ¯à®Ú¥»ªvÀø¯áÅè©Ê¦ÙµäÁY¡C

¦b¦U­ÓÃþ«¬ªºSMA¤¤¡A³ÌÄY­«§Î¦¡¬O1«¬SMA¡C1«¬SMA¥Ñ©ó¹B°Ê¯«¸g¤¸³à¥¢©M¬ÛÃö¦Ù¦×°h¤Æ¡A¤j³¡¤À±wªÌ¦b¨â·³«e´N»Ý­n¥Ã¤[©Ê©I§l¤ä«ù¡C

AveXis¤½¥q¥Ø«e¶i¦æSVXS-101ªº¤T´ÁÁ{§É¸ÕÅç¡AªvÀøSMA1«¬±wªÌ¡C

4¤ë¡A¥t¤@®a·ç¤hÃÄ¥ø¿ÕµØ¤@»ïÅå¤H¡A¥H87»õ¬ü¤¸ªº»ù®æ¦¬ÁʤFAveXis¤½¥q¡C¿ÕµØªº¤J§½¡A§ó¥[¥[¼@¤FSMAªvÀø»â°ìªºª§¹Ü¡C

*********************************************************

JBC¡Gºñ¯ù¤¤ªº¯S®í¤À¤l©Î¯à¦³®Ä§í¨î¤ßŦ¯fµo§@©M¤¤­·µo¥Í

¨Ó·½¡G ¥Íª«¨¦ ¡@2018-06-04

med.sina.com/article_detail_103_1_46856.html

ªñ¤é¡A¤@¶µ¥Zµn¦b°ê»ÚÂø»xJournal of Biological Chemistry¤Wªº¬ã¨s³ø§i¤¤¡A¨Ó¦ÛÄõ¶}´µ¯S¤j¾Ç©M§Q¯÷¤j¾Çªº¬ì¾Ç®a­Ì³q¹L¬ã¨sµo²{¡Aºñ¯ù©Î¯à¦³®Ä§í¨î¦]°Ê¯ßµ°¼Ëµw¤Æ¤Þµoªº¤ßŦ¯fµo§@©M¤¤­·±wªÌªº¦º¤`¡C

¤å³¹¤¤¬ã¨sªÌªí¥Ü¡A¤@ºØ¦s¦b©óºñ¯ù¤¤ªº¯S®í¤Æ¦Xª«¤£¶È¯à°÷­°§Cªüº¸¯÷®üÀq¯f±wªÌ¤j¸£¤¤ªº¾ý¯»¼Ë´³¶ô¥~¡AÁÙ¯à°÷¯}¸H¨Ã¥B¤À¸Ñ¦åºÞ¤¤¼ç¦b¦MÀIªº³J¥Õ½è´³¶ô¡C°Ê¯ßµ°¼Ëµw¤Æ±wªÌ°Ê¯ß¤¤·|¦s¦b¯×ªÕª«½èªº¿n²Ö¡A¨ä·|­°§C±wªÌ¤j¸£©M¤ßŦªº¦å¬y¶q¡A¦b¯e¯fªº±ß´Á¶¥¬q¡A¦W¬°¸ü¯×³J¥ÕA-1¡]apoA-1¡^ªº³J¥Õ½è´N·|§Î¦¨¾ý¯»¼Ë³J¥Õ¨I¿nª«¡A¨äÃþ¦ü©óªüº¸¯÷®üÀq¯f±wªÌ¤j¸£¤¤ªº¨I¿nª«¡A³o¨Ç¨I¿nª«¯à¦b°Ê¯ßµ°¼Ëµw¤Æ´³¶ô¤¤°ï¿n¡A¨ä·|¤£Â_¼W¥[´³¶ôªº¤Ø¤o¡A¶i¤@¨B­°§C±wªÌ°Ê¯ß¤¤ªº¦å¬y¶q¡A¦Ó¥B·|¨Ï±o´³¶ô«D±`¤£Ã­©w¡A±q¦Ó¼W¥[±wªÌ¤ßż¯fµo§@©M¤¤­·ªº­·ÀI¡C

¬ã¨s¤H­ûµo²{¡Aºñ¯ù¤¤³Ì±`¨£ªº¦¨¤À¡X¨à¯ù¯À¡]ªí¨S­¹¤l¨à¯ù¯À¨S­¹¤l»Äà­¡AEGCG¡^©Î³\´N¯àµ²¦XapoA-1¾ý¯»¼Ë³J¥ÕÅÖºû¡A±q¦Ó´N¯à±N³oºØ¾ý¯»¼Ë³J¥ÕÂà¤Æ¦¨¬°¤£¤Ó·|¹ï¦åºÞ³y¦¨·l¶Ëªº¤p«¬¥i·»©Ê¤À¤l¡C

Tannic acid ©M EGCG ³£¦³¦@¦Pªº°ò¥»³æ¦ì---¨S­¹¤l»Ä

¤£ª¾¬O§_¤]¦³Ãþ¦ü¥\¯à ?

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/4 ¤U¤È 03:19:24²Ä862½g¦^À³
liaw6575¤j¤j±a»â§Ú­Ì»{ÃÑ [ «äı¥¢½Õ¯g ] ©M [ ªü¯÷®üÀq¯g ]

liawbf.pixnet.net/blog/post/47963937

.³zµøºë¯«¤Àµõ¯g

.¯d¦í³Ì«á¤@¤ù°O¾Ð¡V²Ó»¡ªü¯÷®üÀq¯g

.¯à¹w¨¾¶Ü¡Hªü¯÷®üÀq¯g

ÁÂÁÂliaw6575¤j¤j¤Þ¤¶

ÁÂÁ¤j®a!

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/6/4 ¤W¤È 09:51:27²Ä861½g¦^À³
²q·Q¤j...

·PÁ´£¨Ñ³Ìªñ¤½¥q¬ÛÃö°T®§...§Ú¨Ó¸É¥R¤@­Ó©M§Aªº¤G¤T¨Æ¥i¯à¦³Ãöªº...

¥»¦¸¿W¥ß¸³¨Æ­Ô¿ï¤H¦W³æ...³\¥ü¼yªk¾Ç³Õ¤h...

°õ·~¸g¾ú:

¦b°ê¤º¤Î¸ó°ê°Ó °È»Pª§ºÝ³B²z¡B«H°Uªk¡B¸ê²£³W¹º¡BÃÒ¨é¥æ©öªk¡B

´¼¼z°]²£Åvªk¤Î¤£°Ê²£ªkµ¥»â°ì¦³Â×´I¸gÅç¡A¨Ã¦b¤j¾Çªk«ß¨t¾á¥ô¬ÛÃö±Ð¾¡C

³\«ß®v´¿¾á¥ô¦a¤èªk°|ªk©x¶W¹L¤Q¦~

¥D­n±M·~»â°ì:

«H°Uªk¡B¸ê²£³W¹º¡BÃÒ¨é¥æ©öªk¡Bª§ºÝ³B²z¡B´¼¼z°]²£Åvªk

¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò~~

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/3 ¤U¤È 04:49:50²Ä860½g¦^À³
SyneuRx ¤½¥qªñ¨Ó¤G¤T¨Æ

Uspto Issues Trademark: Syneurx

www.highbeam.com/doc/1P4-2020372070.html

The trademark SYNEURX (Reg. No. 5419038) was issued on March 6 by the USPTO.

*****************************

SyneuRx Neuroscience HK Limited (CR No. 2684857)

www.hkcompanycheck.com/syneurx-neuroscience-hk-limited-clxcfee/

SyneuRx Neuroscience HK Limited was incorporated on 23 Apr 2018 as a Private company limited by shares registered in Hong Kong.

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/3 ¤U¤È 02:56:32²Ä859½g¦^À³
¡u10­Ó¦³8­Ó§Ù¤£±¼¡v Âå15¦~«e­ºµo²{K¥L©R¶Ë»H¯Ö

2018-06-03 14:25Áp¦X³ø °OªÌ½²®e³ì¢¬§Y®É³ø¾É

udn.com/news/story/7266/3177414?from=udn_ch1cate6649_pulldownmenu

½ÃºÖ³¡²Î­pµo²{¡AK¥L©R¤´¬O¦M®`¦~»´¥@¥N³ÌÄY­«ªº¬r«~¡C°ª¥«Áp¦XÂå°|ªc§¿¬ì¥DªvÂå®v½²¨q¨k2003¦~±qÁ{§É®×¨Òµo²{¡A§l­¹K¥L©R·|¾É­P»H¯ÖÅÖºû¤Æ¯fÅÜ¡A°ê¥~ª½¨ì2007¦~¤~¦³¬ÛÃö®×¨Òµoªí¡F§Y«K¦h¦~¨Óªc§¿¬ìÂå®v¤£Â_¦V¯f±w«Å¾É¡A¥L·P¹Ä¡u15¦~¨Ó¯f±w¤¤10­Ó¦³8­Ó§Ù¤£±¼¡I¡v

½²¨q¨kªí¥Ü¡A15¦~«e¤@¦W24·³¤k«Ä¦]ÀW§¿¡B¦å§¿¨D¶E¡A¦Û­z¤@¤Ñ­n¤W20¦¸´Z©Ò¡Aµh¤£±ý¥Í¡FX¥úÀˬdµo²{¤k«Ä»H¯ÖÅËÁY¡B»H¯Ö¾ÀÅÜ«p¡A§ó±q»H¯ÖÃè¤W¬Ý¨ì»H¯Ö¾À¼ìÄê¡B¥X¦å¡A¥u¯à¥Î¡uºG¤£§Ô¸@¡v§Î®e¡C

½²¨q¨k»¡¡A¨º°}¤l¦]±Æ§¿»Ùê¨D¶Eªº¦~»´±wªÌÅܦh¡AÅý¥L¦Ê«ä¤£±o¨ä¸Ñ¡Aª½¨ìÅ@²z®v¦b¤@¦Wªì¶E±wªÌ¯f¾ú¤W¼gµÛ¡u¤w©ÔK¤@¦~¡v¡A¥L«éµM¤j®©¡AÀH«á°w¹ï³o¸s±wªÌ®i¶}¤@¨t¦C§¿²G¡B¦å²G¤Î¬r¤Æª«Àˬd¡A½T»{¬OK¥L©R¤¤ªº¤Æ¾Çª«½è¹ï»H¯Ö³y¦¨¶Ë®`¡A¤w¦b2004¦~¥¿¦¡µoªí¬ã¨sµ²ªG¡C

15¦~¨Ó¡A§l­¹K¥L©Rªº¦~»´¤H¤f¦³¼WµL´î¡A½²¨q¨k·P´nªí¥Ü¡A©ú©ú8¡B9¦¨±wªÌ¥i³z¹LÃĪ«Àò±o«Ü¦nªºªvÀø®ÄªG¡A¦ý¦³8¦¨±wªÌ¦b¯gª¬§ïµ½«á«ùÄò§l­¹K¥L©R¡A¦~¬ö»´»´´N¨â°¼µÇ¤ô¸~¡B¬Æ¦Ü±o¤Á°£»H¯Ö¡C¥L»¡¡A³Ì¦­¦¬ªvªº10­Ó±wªÌ¤¤¡A¥u¦³2¤H¦¨¥\§Ù±¼¡A¡u¤@­Ó¬O¦]¤JºÊªA¦D¡A¤@­Ó«h¬O³Q°e¥X°ê¥´¤u«×°²¡I¡v

·|­û:®ÇÆ[ªÌ10141545µoªí®É¶¡:2018/6/3 ¤U¤È 12:10:47²Ä858½g¦^À³
·PÁª©¤W¤j¤jªº±M·~¸ê°T

­Ó¤H·Qªk

­ÓªÑ±q°ª»ù230¦V¤U¦ôºâ³Ñ¤U2¦¨§C»ù¦b46¤¸¤Ï¼u¨ì¤µ80¥H¤W...¥«³õ«Ü¦h¬ÛÃö­ÓªÑ¬O¦p¦¹ÅܤÛ

¤½¥q§V¤O¤£ÅÜ®ø®§°t¦X¥X²{ªÑ»ù¤´Äò¤W¦æ....§Æ±æ¤½¥q§V¤O¦³¦¨

¼Æ¦~«eªLºaÀA¥ý¥Í´¿¨¥·sÃÄ¥¼¨Ó¸û¯àÁÈ¿ú¦³Àù¯gÃĤκ믫¯fÃÄ...©Ò¥H¤j®aÁͤ§­Yõ­¶R6575¦¹±m¨é

§ë¸ê­·ÀI«ä¦Ò90%¥¢±ÑÂÔ·V¬°¤W...¨SÀò§Q§O¶R¦h¦]¬°¨SÀò§Q¬O¯u....·í§ë¸ê¾Ç²ß¦¨ªø

¬Û¹ï·Qªk¤£ÅÜ....Àò§Qªº¥Í§ÞÂåÀø«O°·­¹«~ªÑ¨ÌµM¤@¤ù¤Ñ

·|­û:²q·Q10136148µoªí®É¶¡:2018/6/2 ¤U¤È 05:18:02²Ä857½g¦^À³
ªüº¸¯ý®üÀqÁ{§É¸ÕÅç±µ³s¥¢±Ñ¥Íª«ÂåÃÄ¥¼¨ÓÁٯవ¤°»ò¡H

¨Ó·½¡G·s®öÂåÃÄ·s»D ¡@2018-06-02

med.sina.com/article_detail_103_2_46664.html

¦pªG·í«e©Ò»{¬°ªºAD¥D­n¯f¦]³Ì²×³QÃÒ©ú¬O¤£¦¨¥ßªº¡A§Ú­ÌÁٯవ¨Ç¤°»ò¡H

1¡B§K¬Ì¯«¸g¾Ç

·í«e¡AÃö©óADµo¯f¾÷¨îªº¤@­Ó¤é¯q¬y¦æªº°²»¡¬O¡A¸Ó¯f¹ê»Ú¤W¬O¥Ñ¤j¸£¤¤ªºª¢¯g©Î¯«¸gª¢¯g¤Þ°_ªº¡C

§¨Ó¯«¸g¬ì¾Ç°ª¯Å¥DºÞJennifer Lairdªí¥Ü¡A§K¬Ì¯«¸g¾Ç¬O§¨Ó«D±`·P¿³½ìªº¤@­Ó»â°ì¡A¦ý¸Ó»â°ì¤´³B©ó«Ü¦­ªº¶¥¬q¡C

2¡BªíÆ[¿ò¶Ç¾Ç

¦è¯Z¤ú¥Íª«§Þ³N¤½¥qOryzon Genomics¤w¸g±Ò°Ê¤F¼Æ­ÓÁ{§É¸ÕÅç¡A¥Î¤@ºØÃĪ«¦P®É¹v¦V2ºØªíÆ[¿ò¶Ç酶¡A³o¨Ç酶±±¨îµÛ»PAD¬ÛÃöªº¦h­Ó°ò¦]¡C

¦b¬ü°ê¡A¦Ê°·©MRodin Therapeutics¤]¦b¶}®iÁ{§É«e¬ã¨s¡A½Õ¬d¥t¤@ºØªíÆ[¿ò¶Ç¾ÇÃĪ«¡A³oºØÃĪ«¹v¦V¯«¸g¬ðIJ¼u©Ê¡]synaptic resilience¡^¡A¤£¬OÃöª`©ó´î¤Ö¯«¸g¤¸ªº¥á¥¢¡A¦Ó¬O«OÅ@¯«¸g¤¸¤£¥¢¥h¥¦­Ì¤§¶¡ªº¬ðIJ³s±µ¡C

3¡B·L¥Íª«²Õ¾Ç

·í«e¡A¤H­Ì¤é¯qÃöª`ªº¥t¤@­Ó¬ã¨s»â°ì¬O·L¥Íª«²Õ¡]microbes¡^¡C¥Ø«e¤wª¾¡A¥Í¬¡¦b§Ú­Ì¸z¹D¤¤ªº·L¥Íª«²Õ¯à³q¹L©Ò¿×ªº¸z-¸£¶b¡]gut-brain axis¡^¼vÅT§Ú­Ìªº¤j¸£¡A¥¦­Ì¤w»Pºë¯«¯e¯f¡]¦p©¬ª÷´Ë¯f¡^¥H¤Î¯«¸g°h¦æ©Ê¯e¯f¡]¦pAD ¡^ÃöÁp°_¨Ó¡C

AD»P·s³¯¥NÁ¤§¶¡ªº½Ñ¦hÃöÁp¤¤¡A¬ã¨s³Ì¦hªº¤@­ÓÃöÁp¬OÁx©T¾J¡C¾¨ºÞ¥Ø«eÁÙÃÒ¾Ú¤£¨¬¡A¦ý¦³¤@¨Ç¬ã¨s«ü¥X¡AÁx©T¾J¦b¤j¸£¤¤ªº¿n²Ö¥i¯à¥[³tADªº¶i®i¡C¥Ø«e¡A¤@®a¦W¬°Brain Vectisªºªk°ê¤½¥q¥¿¦b§Q¥Î³o¤@°²»¡§@¬°¶}µo¤@ºØ°ò¦]Àøªkªº°ò¦¡A¸Ó°ò¦]Àøªk¦®¦b¬@±Ï¤j¸£¤¤ªº¥¿±`Áx©T¾J¥NÁ¡A­º­Ó¤HÅéÁ{§É¸ÕÅç¹w­p±N¦b2021¦~±Ò°Ê¡C

4¡B°ò¦]Àøªk

°ò¦]Àøªk¦³±æ¦¨¬°ªvÀøADªº¥t¤@ºØ¤â¬q¡C¾¨ºÞ­º§åÁ{§É¸ÕÅ礤¦³¤@­Ó¤w¸g¥¢±Ñ;¦ý³oºØªvÀø¤èªk¤w³QÃÒ©ú¬O¦w¥þªº¡A¨Ã¥B­@¨ü©Ê¨}¦n¡C¥¼¨Óªº¬ã¨s¡A¥i¯à±Ä¨ú°w¹ïAD¶i®i¦³¹ê½è©Ê¼vÅTªº¨ä¥L¹v¼Ð¶i¦æ´ú¸Õ¡C

**************************************************************************************

¦Ü©ó­f¥Ò»Ä¶uªº¥\¥Î¦³´X­Ó?

liaw6575¤j¤j¼g¤F¨t¦Cªº±M¤å

liawbf.pixnet.net/blog/category/2056459

¨ä¤¤¦³Ãö¸z-¸£¶b¡]gut-brain axis¡^ªº¤j¤å

liawbf.pixnet.net/blog/post/47614899

ÁÙ¦³JOE COHEN ¥ý¥Íªº¥¬¬¥®æ

­f¥Ò»Ä¶u¡]­¹«~¨¾»G¾¯¡^ªº°·±d¯q³B

www.selfhacked.com/blog/sodium-benzoate-some-preservatives-block-inflammation-and-autoimmune-disease/

­f¥Ò»Ä¶u¹ï°·±d¼vÅTªºÁ`µ²

­f¥Ò»Ä¶u¡G

.³q¹L¼W¥[ªø®Éµ{¼W±j¡]LTP¡^©M¬ðIJ¥i¶ì©Ê¡]R¡^¼W¥[°O¾Ð¤O¨Ã¥B¬O»{ª¾¼W±j¾¯¡C¾÷¨î¬O³q¹LNMDA¿E¬¡¡]R¡^¡C

.³q¹LCREB¬¡¤Æ¡]R¡^¼W¥[¤j¸£¤¤ªº¥Íªø¦]¤l¡A¦p BDNF©M¯«¸gÀç¾i¦]¤l-3 ¡C

.¹³¤@¨Ç¥L¥ÅÃþÃĪ«¤@¼Ë­°§CÁx©T¾J¡]R¡^

.­f¥Ò»Ä¶u´î¤Öª¢¯g©MÁx©T¾J

.­f¥Ò»Ä¶u©MD-®ò°ò»Ä®ñ¤Æ酶

.»{ª¾¼W±j

.­f¥Ò»Ä¶u¦p¦ó­°§C¦Û¨­§K¬Ì©Mª¢¯g

.­f¥Ò»Ä¶u¦p¦ó­°§CÁx©T¾J©M­°§Cª¢¯g

Immunomodulation of experimental allergic encephalomyelitis by cinnamon metabolite sodium benzoate

(¦×®Û¥NÁª«­f¥Ò»Ä¶u¹ï¹êÅç©ÊÅܺA¤ÏÀ³©Ê¸£¯áÅ誢ªº§K¬Ì½Õ¸`§@¥Î)

Kalipada Pahan

www.ncbi.nlm.nih.gov/pmc/articles/PMC3206174/

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/29 ¤U¤È 08:39:24²Ä856½g¦^À³
¬K©M´º©ú¤j..

¤£¥Î·Q¤Ó¦h°Õ...

¥i¥H¬Ý¤@¤U liaw6575¤j¤j¤µ¤é±M·~ªº·s§@ SNG-12 PK SAGE-217 ºë±m¤ÀªR..

¤å¤¤­«ÂI SNG-12¤G´Á¸ÕÅ禳°µ¨ì6©Pªø´ÁªvÀø..SAGE-217¥u°µ¨ì2©P...

¦Ó¥BSNG-12¶VªøªvÀø,®ÄªG¶q¶V¤j,¥iªø´Á¨Ï¥Î...

¬O§_SAGE-217¥iªø´Á¨Ï¥Î?­«½Æ¨Ï¥Î¦³µL¦w¥þºÃ¼{?¤´«Ý¬dÃÒ...

¶i«×¹ï¤ñ...SNG-12¶i«×¤W¥Ø«e¬O»·»·¶W«e..¤w®Ö­ã¶i¤J¤T´Á...

¼~Æ{¯g¨C¦~116»õ¬üª÷¥H¤Wªº¥«³õ...´Á«Ý½²±Ð±Â¹Î¶¤¦­¤é§¹¦¨·sÃĬãµo..Åý·sÃĤW¥«!

¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò~~

liawbf.pixnet.net/blog/post/47956260

·|­û:¬K©M´º©ú10141799µoªí®É¶¡:2018/5/28 ¤W¤È 12:07:10²Ä855½g¦^À³
²q·Q¤j

ÁÂÁ±z´£¨Ñ·Qªk©M¼Æ¾Ú¤ä«ù

¦Û¤v¤@­Ó¤HÁ`¬O·|·Q¤Ó¦h

³o®É­Ô´N·|»Ý­n¹Ù¦ñ¨Ó°í©w«H¤ß

·|­û:¬K©M´º©ú10141799µoªí®É¶¡:2018/5/28 ¤W¤È 12:00:26²Ä854½g¦^À³
¤p©¯¹B¤j

§Ú¬O»{¬°´N¹³FDAµ¹¤¤¸ÎÁ{§É¤H¼ÆÀu´f¥H¤Î

¤ß®®SND12¦bÃøªv«¬ºë¯«¤Àµõ¯gª§¨ú¨ì©t¨àÃĸê®æ

¤@¼Ë

§Ú­Ì³£¤£·|ª¾¹D±µ¤U¨ÓªºÁ{§ÉSAGE-217¬O§_·|¦]¬°BTD¸ê®æ©M¼Æ¾Ú¦Óª§¨ú¨ì¤°»ò

­««×¼~Æ{¯gªºÁ{§É¤£ª`·N¡A¶i«×«Ü§Ö´N·|³Q°l¤Wªº¡A¤£¯à¤Ó¤j·N

·|­û:²q·Q10136148µoªí®É¶¡:2018/5/27 ¤U¤È 10:00:40²Ä853½g¦^À³
ÁÂÁ¬K©M´º©ú¥Sªº¤Þ­z©M´£¿ô

·íSAGE-217ÀòBTDªº¦P®É ¤p§Ì¤]©M±z¦³¦P¼Ëªº·Qªk

¤£¹L¦b³s¦êªº«ä¦Ò«á ¬Ýªk¤w¦³©Ò§ïÅÜ ¦ý¤£ª¾¹ï¤£¹ï

SAGE-217 ·íµM¬O¤@­Ó±j«lªº¹ï¤â

¦Ñ¥v¤j¤j¤]¤ÀªR¤ñ¸û¹LSAGE-217 ©M SNG-12ªºÃÄ®Ä

¸Û¦p±z©Ò´£ªº

¡§ SAGE-217¥i´£°ª¤F¯f±w¾ãÅéºÎ¯v®É¶¡¤ÎºÎ¯vºûÅ@85% (30mg ªº¥ÎÃÄ) »P 88% (45mg ªº¥ÎÃÄ)¡C¦w¼¢¾¯ªººÎ¯v¦³®Ä²v¤¤¦ì¼Æ´£¤É¤F 73%¡C¼Æ¦r®t¶Z¤£¤j . ¡§

¦w¼¢¾¯ªº®ÄªG«Ü°ª ©M¦Ñ¥v¤j¤jªº´£¥Ü¬Û¦P

¦AªÌ

SNG-12¤]¯à­°§C¥¢¯v©M¯«¸gµJ¼{

HAMD-17ªº¥¢¯v / ¯«¸gµJ¼{¤À¼Æ¥­§¡¥Ñ 6.6 ¤À­°§C¨ì 3.07 ¤À

©M citalopram ¬Û¤ñ¹F0.01ÅãµÛ¤ô·Ç ®ÄªG¶q 0.99

½Ð°Ñliaw6575¤j¤jªº±M¤å liawbf.pixnet.net/blog/post/47559201

§Ú¤£ª¾¹D³o¦p¦ó¤ñ¸û±EÀu ?

¤TªÌ

SNG-12¦h¤F¤@¶µªvÀø¦Û±þ·N©À

Liaw6575¤j¤jªº¤j¤å ¡§ §Ü¼~Æ{SSRIÃĪ«´£°ª¦Û±þ²v? SNG-12ªº¾÷·| ¡¨

liawbf.pixnet.net/blog/post/47448768

¤j¤j¦a¼W¥[SNG-12ªºªþ¥[»ù­È ? ©Î»P¥«³õ°µ¥X°Ï¹j ?

¥xÆW¥«³õµ¹¤ß®®ªºµû»ù ·|§_¤Ó¼ÖÆ[ ? §Ú¤£ª¾¹D

¦ý¤ñ¤§SAGE ¤W©P¤­¦¬½LªºÁ`¥«­È 72.225 »õ¬ü¤¸

¦P¼Ë¾Ö¦³¨â­ÓBTD

¤ß®®´X¥G¬O¤H®aªº§À¼Æ¦Ó¤w

¤p§ÌÆ[ÂI©Î¥¢¤§°¾»á

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/27 ¤U¤È 09:54:11²Ä852½g¦^À³
¬K©M¤j¤j...

§A¶Kªº¨º½gSAGE-217¬O¤µ¦~2¤ëªº³ø¾É...¼g¨ì¬OSAGE-217¦b¹êÅçµo²{...

²{¦b¦pªG¦³¶i«×ªº¸Ü...SAGE-217³Ì¦hÀ³¸Ó¥u¦b1¦Ü2´Á§a...

¦ý..¥Ø«e¤ß®®¤w¸g³q¹L2´Á...FDA®Ö­ã¶i¦æ¤T´ÁÁ{§É¤F...

·sÃĶi¤J¤T´ÁÁ{§É..¯f¤H¹ï¤ß®®3´Áªº·sÃÄ...¬Û¹ï«H¤ß«×·|¤ñ¸û°÷³á...

¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò

·|­û:¬K©M´º©ú10141799µoªí®É¶¡:2018/5/27 ¤U¤È 08:00:19²Ä851½g¦^À³
Àò±o­««×¼~Æ{¯gBTDªºSAGE-217¬O¦³«Â¯Ù©ÊªºÄvª§¹ï¤â

§Ú»{¬°­nª`·NSAGE-217ªºÁ{§É¶i«×

§Ú·Q¦bÁ{§É¦¬®×¤W¤]¬O

SNG12¤T´Á©MSAGE-217¤Ó±µªñ¤]¤£¤Ó¦n

Á{§É­n¬D¯f¤H¡A¯f¤H¤]¤@¼Ë¬O­n¬DÁ{§É°Ñ¥[ªº

¼~Æ{¯gÃĪ«·N¥~¹ï¥¢¯v±wªÌµo´§®ÄªG SageªÑ»ù«G²´

news.cnyes.com/news/id/4031396

³o½g·s»D¸Ì´£¨ì

SAGE-217¥i´£°ª¤F¯f±w¾ãÅéºÎ¯v®É¶¡¤ÎºÎ¯vºûÅ@

85% (30mg ªº¥ÎÃÄ) »P 88% (45mg ªº¥ÎÃÄ)¡C¦w¼¢¾¯ªººÎ¯v¦³®Ä²v¤¤¦ì¼Æ´£¤É¤F 73%¡C

¼Æ¦r®t¶Z¤£¤j¡AÁÙ¬O­È±o°lÂÜ«áÄòÁ{§É¹êÅç

¼~Æ{¯g±wªÌ ¤E¦¨·|¥¢¯v

news.ltn.com.tw/news/life/paper/247197

±q³o½g¤å¥i¥H¤F¸Ñ

¼~Æ{¯g±wªÌ¹ï©óºÎ¯v§ïµ½¦³¬Û·íªº»Ý¨D©Ê

ªø¤[¥H¨ÓÁ{§É¤]Ãҹ꦳¨Ç¦w¯vÃĬO·|¦¨Å}ªº¡A¦w¯vÃĪº¦¨Å}«ÜÃø³B²z¡A¤£¤ñ§Ù¬r®e©ö

·Pı¤W¹ï¯f±w¨Ó»¡SAGE-217¥iªvÀø¼~Æ{¯g¤S¯à§ïµ½¥¢¯v¡A¬O¤@­Ó«Ü¦nªº¿ï¾Ü

ÁöµM¤Ï´_ªA¥ÎSAGE-217¤Îªø´Á©ÊªA¥Î¹ï©ó®ÄªGªº¼vÅTÁÙ¥¼³Q±´°Q

¦ý¤£¯à¤Ó´Á«Ý¹ï¤âªºªø´Á¦w¥þ©Ê¥X°ÝÃD

SNG12ªºÀø®Ä«ü¼Ð¬°¦Û±þ¯gª¬«Ü´Î¡A¹ï¯f±w¨Ó»¡ºÎ¯v«~½è¯à§ïµ½¤]¬O«Ü¦n

¥i¯à¥HÁ{§É¨Ó»¡·|­«µø¦Û±þ¡A¥Í©R¬O³Ì­«­nªº

¤£¹L¤]¤£±Æ°£¯f±w¶¡¥i¯à·|¦]¬°ºÎ±o¦n©E¦n¹D¬Û报¡A¼W¥[©MÂå®v°Q½×§ïªA¥ÎSAGE-217ªº¥i¯à©Ê

¤£¯à¤Ó¼ÖÆ[

¤W¥«®É¶¡¤Ó¬Ûªñ§Ú·|¾á¤ß¬O±j¹ï±jµw¸Iµw¡A¦A¨Ó­n¤ñªº·|¬O±ÂÅv¹ï¶H°÷¤£°÷¦³¤O¤F

·|­û:²q·Q10136148µoªí®É¶¡:2018/5/27 ¤U¤È 01:37:30²Ä850½g¦^À³
½²±Ð±Â½ÍNMDAR,³o·|¬O¤ß®®¬ãµo¾úµ{ªº²z½×µù°O¶Ü¡H

½²±Ð±Â¥Î¤FGrand regulator¨Ó§Î®e¡A³o·|¤£·|¬OCNS»â°ìªº Grand Slam?

Editorial (Thematic Issue: Regulating the CNS Grand Regulator; N-methyl-D-aspartate Receptor-Mediated Neurotransmission)

Author(s): Guochuan Emil Tsai.

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 32 , 2014

DOI : 10.2174/1381612820666140204121732

5/24 ¤ß®®µo¤FSNG-12 ªº¸É¥R¤½§i¡A¨ì©³¬O£¸­Ó¤°»ò¼ËªºÂà§é¡H

¦n·Qª¾¹D§r¡I

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a¡I

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/25 ¤W¤È 10:23:26²Ä849½g¦^À³
¬Q¤é¤½§iªº¤º¤å..¬Ýªº¥X¤½¥q¦³¬Û·í¤jªº«H¤ß¬ãµo¥X¶W¶V²{¦³¼~Æ{¯gÃĪ«ªº·sÃÄ...

¤]´Á«Ý¥¼¨Ó¤½¥q¦³±æ¥Ó½Ð²Ä3±iBTD...

--------------------------------------------------------------------------------

¥»¤½¥q«h¬O³z¹L¥ÌÓi»Ä§í¨î¦A¦^¦¬¾÷Âà(glycine transporter-1 inhibition)¡A¼W¥[

¬ðIJ¶¡ªº¥ÌÓi»Ä¿@«×¥H¬¡¤ÆNMDA¥\¯à¡A¦b¥ý´ÁÁ{§É¸ÕÅç¡A¹ï¼~Æ{¤Î¦Û±þ¯gª¬ªºªvÀø®Ä

ªG¬Ò§Ö©ó¡B³Ó©ó¿ï¾Ü©Ê¦å²M¯À¦A§l¦¬§í¨î¾¯ Citalopram¡A¨Ã¥B¦bÃĪ«¦w©w©Ê¤Î±M§Q

¦³¬ð¯}«á¡A¶i¤J¤T´ÁÁ{§É¸ÕÅç¡C

--------------------------------------------------------------------------------

´Á¬ß¤½¥q¥¼¨Ó¯àÂǥѴ£¨Ñ²{ªp¸ê°T...Åý¼s¤jªº§ë¸ê¤H¹ï¤ß®®ªº¬ãµo¦³§ó¦hªº»{ÃÑ...

¥H¤W~~·PÁÂ~~

·|­û:²q·Q10136148µoªí®É¶¡:2018/5/24 ¤U¤È 05:45:26²Ä848½g¦^À³
¹ï©ó¤½¥q¦A¸É¥R¤½§i

§i¶D§ë¸ê¤j²³¼~Æ{¯gÃĪ«¥«³õ²{ªp , µ¹¤©©ç©ç¤â

§Æ±æ¤½¥q¥¼¨Ó¦h¦h»¡©ú , Åý§ë¸ê¥«³õ¹ï¤ß®®ªº¬ãµo¦³§ó¦hªº»{ÃÑ

ÁÂÁ½²±Ð±Â

¥t¥~,¤½§i¤¤ªº²Ä(5)¶µ

[(5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G±N®Ú¾Ú¥»´ÁÁ{§É¸ÕÅçµ²ªG¨M©w¬O§_»Ý­n¶i¦æ¡C]

³o¦³¦ó·N²[¶Ü?

³o¬O»¡

¥Ø«e¦b¨S¦³BTDªº±¡ªp »Ý°µ¨â­ÓÁ{§É¤T´Áªº²Ä¤G­Ó¶Ü?

§í©Î¬O

°µ§¹³o­Ó¤T´Á ±NµøÃĮı¡ªp ¥Ó½ÐBTD? ¦]¬°¥Ø«e¦Û±þ¯gª¬¨ÃµLÃĪ«ªvÀø ¦Ó¿ï¾Ü³o­Ó¬ð¯}¤f?

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/24 ¤U¤È 05:14:14²Ä847½g¦^À³
¤W¤å¸ê®Æ¥´¤Ó§Ö...¥´¦¨117»õ¤F...

------------------------------------------------------------------

·PÁ¤½¥q²Ó¤ß´£¨Ñ¥h¦~³Ì·s¥«³õ²{ªp¬ù 116»õ¬ü¤¸...

-------------------------------------------------------------------

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/24 ¤U¤È 05:05:49²Ä846½g¦^À³
´M³V¤j...

¥Ø«e¥h¦~¥«³õ´N¦³116»õ¬üª÷³á...50»õ¬üª÷¬O«ü2012¦~.¨º¦~½æ³Ì¦nªº§Ü¼~Æ{ÃĪ«...

¥Ø«e¼~Æ{¯gªº¥«³õ...¨Ì¤½¥q³Ì·s´£¨Ñªº¸ê®Æ...

¥h¦~2017¦~§Ü¼~Æ{ÃĪ«ªº¥«³õ..¤j¬ù116»õ¬üª÷...

¹w¦ô2018-2023¦~ªº¦~½Æ¦X¼Wªø²v¬ù1.8%¡C

------------------------------------------------------------------------------------------------------

®Ú¾Ú¥«³õ¬ã¨s¡A2017¦~¥þ²y§Ü¼~Æ{ÃĪ«(antidepressants)¤j¬ù116»õ¬üª÷¡A

¹w¦ô2018-2023¦~ªº¦~½Æ¦X¼Wªø²v¬ù1.8%¡C

------------------------------------------------------------------------------------------------------

¥»¤H5/23 µo¤åªº90»õ¬ü¤¸¥«³õ¸ê°T¬°2016¦~¬Ý¨ìªº¹w¦ô..

·PÁ¤½¥q²Ó¤ß´£¨Ñ¥h¦~³Ì·s¥«³õ²{ªp¬ù117»õ¬ü¤¸...

¥i¨£¼~Æ{¯gÃÄ«~¥«³õ¬O°ª¦¨ªø©Ê...¦ý³o¤]¥Nªí¯f¤H¤£Â_¼W¦h...

´Á¬ß¤½¥q¯à¦­¤é®³¨ìÃÄÃÒ...±N§ó¦³®ÄªºªvÀø±À¼s¦Ü¥þ¥@¬É¦³»Ý­nªº¯f¤H¡C

·P®¦!

¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸êªÌ°Ñ¦Ò...

·|­û:´M³V10132258µoªí®É¶¡:2018/5/24 ¤U¤È 04:40:52²Ä845½g¦^À³
¤½¶}¸ê°TÆ[´ú¯¸­«¤j°T®§¤½§i

(6575)¤ß®®-¤½§i¥»¤½¥q¬ãµo¤¤­««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡AÀò±o¬ü°ê­¹«~ÃĪ«ºÞ²z§½(FDA)®Ö­ã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç(¸É¥R¤½§i)

1.¨Æ¹êµo¥Í¤é:107/05/24

2.¤½¥q¦WºÙ:¤ß®®¥ÍÂåªÑ¥÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î

5.µo¥Í½t¥Ñ:¥»¤½¥q¬ãµo¤¤­««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡AÀò±o¬ü°ê­¹«~ÃĪ«ºÞ²z§½(FDA)®Ö­ã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç¡C

(1)¬ãµo·sÃĦWºÙ©Î¥N¸¹:SNG12¡C

(2)¥Î³~¡G¼~Æ{¤Î¦Û±þ¯gª¬¡C

(3)¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¤T´Á¤HÅéÁ{§É¸ÕÅç¡C

(4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G

A.´£¥X¥Ó½Ð/³q¹L®Ö­ã/¤£³q¹L®Ö­ã¡G­««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡AÀò±o¬ü°ê­¹«~ÃĪ«ºÞ²z§½(FDA)®Ö­ã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç¡C

B.¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G±N¨Ì¸ÕÅç­pµe¶i¦æÁ{§É¸ÕÅç¡C

C.¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G·s¥x¹ô43,303¥a¤¸¡C

(5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G±N®Ú¾Ú¥»´ÁÁ{§É¸ÕÅçµ²ªG¨M©w¬O§_»Ý­n¶i¦æ¡C

A.¹w­p§¹¦¨®É¶¡¡G¹ê»Ú®Éµ{±N¨Ì°õ¦æ¶i«×¨M©w¡C

B.¹w­pÀ³­t¾á¤§¸q°È¡GµL¡C

(6)¥«³õ²{ªp:­««×¼~Æ{(Major depressive disorder)¬O«Ü±`¨£ªººë¯«¯e¯f¡A¨C­Ó¤H²×¨ä¤@¥Í¬ù

¦³15%ªº¥i¯à©Ê¿©±w¦¹¯e¯f¡A¥þ²y­«Æ{±wªÌ¤j¬ù¤T»õ¤H¡C¾¨ºÞ³o¬O«Ü±`¨£ªººë¯«¯e¯f¡A¥B±w¯f²v±N¦]¦U¦¡¥Í¬¡ªÀ·|ÅܾE©Ò²£¥ÍªºÀ£¤O¦Ó³vº¥¤É°ª¡A¦ýÃĪ«¥«³õªº¦¨ªø²v«o¥¼¨£Ãzµo¡A¥D­n­ì¦]¦b©ó¡uÃĮĦ³­­¡v(Ãø¥H©M¦w¼¢¾¯°Ï¤À)¡B¡u¥¼¦³·s¾÷Âà·sÃÄ¡v¡B¡u¾Ç¦WÃÄ¥R¥¸¡vµ¥¡C®Ú¾Ú¥«³õ¬ã¨s¡A2017¦~¥þ²y§Ü¼~Æ{ÃĪ«(antidepressants)¤j¬ù116»õ¬üª÷¡A¹w¦ô2018-2023¦~ªº¦~½Æ¦X¼Wªø²v¬ù1.8%¡C

²{¦³§Ü¼~Æ{¾¯ÃĪ«³£°ò©ó³æÓi°²»¡¡C1950¦~¥N³æÓi®ñ¤Æ»Ã¯À§í¨î¾¯(monoamine oxidase inhibitors)¡B¤TÀô§Ü¼~Æ{ÃÄ(tricyclic antidepressants)¥ý«á°Ý¥@¡AµM¦¹¤GÃþÃĪ«°Æ§@¥Î¸û°ª¡A¥B«D±M¤@©Êªº§í¨î¯«¸g¶Ç¾Éª«½è¦A¦^¦¬¡F1980¦~¥N²Ä¤G¥N§Ü¼~Æ{ÃĪ«½Ï¥Í¡A°Æ§@¥Î¸û§C¥B§í¨î¯«¸g¶Ç¾Éª«½è¦A¦^¦¬ªº±M¤@©Ê°ª¡A¥i¥H¼W¥[¬ðIJ¶¡¯S©w¯«¸g¶Ç¾Éª«½èªº¿@«×¡AºÙ¬°¿ï¾Ü©Ê¦å²M¯À¦A§l¦¬§í¨î¾¯(selective serotonin reuptake inhibitors¡FSSRIs)¡A§¨Ó¤½¥qªºFluoxetine(°Ó«~¦W¡G¦Ê¼~¸ÑProzac)¡B¸¯Äõ¯ÀªºParoxetine (°Ó«~¦W¡G§J¼~ªGSeroxat) ¬O¸Ó®É

´Áªº¥NªíÃĪ«¡C¦Ê¼~¸Ñ±M§Q«OÅ@©ó2001¦~¨ì´Á«á¡A§¨Ó¤½¥qDuloxetine(°Ó«~¦W¡G¤d¼~¸ÑCymbalta) ©ó¬J¦³¦å²M¯À¾÷Âà¤W¦A¥[¤J§í¨î¥¿µÇ¤W¸¢¯À¦A¦^¦¬(serotonin-norepinephrine reuptake inhibitor¡FSNRIsÃþÃĪ«)¡A2012¦~³Ð³y¹O50»õ¬üª÷ªº¾P°âª÷ÃB¡C«áÄòÃĪ«¦h¦b³æÓi¾÷Âà¶i¦æ§ï¨}¡A¦pBupropionÄÝ©ó§í¨î¥¿µÇ¤W¸¢¯À¡B¦h¤ÚÓi¦A¦^¦¬¡C

¦Û¦Ê¼~¸Ñ°Ý¥@«á¡A¥þ²y§Ü¼~Æ{¥«³õÀò±o§Ö³t¶i®i¡AµM´N¦¹¤G¤Q¦h¦~ªº¥ÎÃĸgÅçµo²{¡AµL½×¬OSSRIs©ÎSNRIsÃþÃĪ«¡A¤j·§¥u¹ï35%ªº¯f±w²£¥Í®Ä¥Î¡A¦Ó¥B©¹©¹»ÝªAÃļƶg«á¤~·|³vº¥¦³ÃĪ«§@¥Î¡AµLªk¹ïºò«æªº¦Û±þª¬ªp¦³©ÒÀ°§U¡A«Ü¦h®É­Ô¬Æ¦ÜµLªk©M¦w¼¢¾¯®Ä¥Î°Ï§O¶}¨Ó¡A³o¨Ç¯ÊÂI©úÅãµLªkº¡¨¬¼s¤jªº±wªÌ©Ò»Ý¡C³·¤W¥[Á÷ªº¬O¡A2004¦~¬ü°ê­¹«~ÃĪ«ºÞ²z§½µo¥¬§Ü¼~Æ{ÃĪ«ªº²Î¤@ĵ¥Ü(black box warning)¡A »{¬°25·³¥H¤U¦~»´±Ú¸s¨Ï¥Î§Ü¼~Æ{ÃĪ«¦³¼W¥[¦Û±þ·N©Àªº­·ÀI¡C¬O¬G¾Ç¬É¡BÃĬɫùÄò´M¨D³æÓi¥H¥~ªº·sªvÀø¾÷Âà¡A§Æ±æ¯à¶}µo¥XÃĮħó¦n¡B§@¥Î®É¶¡§óµu¡B°Æ§@¥Î§ó§C¡A¬Æ¦Ü¥i¥H­°§C¦Û±þ·N©Àªº·s¾÷ÂàÃĪ«¡C¥Ø«e¬ONMDAªº½Õ±±¤Þ»â­·¼é¡A¦pAllerganªºRapastinel¬ONMDA³¡¤À«ú§Ü¾¯¡A J&JªºEsketamine¬ONMDA«ú§Ü¾÷¨î¥H§Ö³t­°§C¦Û±þ·N©À(¦ý¬O¦³Ãþ¦ü¨Ï¥ÎK¥L©Rªº­·ÀI)¡C¥t¥~¦³Sage Therapeutics±Ä¥ÎGABA¥¿¦V²§¦ì½Õ±±¡C

¥»¤½¥q«h¬O³z¹L¥ÌÓi»Ä§í¨î¦A¦^¦¬¾÷Âà(glycine transporter-1 inhibition)¡A¼W¥[¬ðIJ¶¡ªº¥ÌÓi»Ä¿@«×¥H¬¡¤ÆNMDA¥\¯à¡A¦b¥ý´ÁÁ{§É¸ÕÅç¡A¹ï¼~Æ{¤Î¦Û±þ¯gª¬ªºªvÀø®ÄªG¬Ò§Ö©ó¡B³Ó©ó¿ï¾Ü©Ê¦å²M¯À¦A§l¦¬§í¨î¾¯ Citalopram¡A¨Ã¥B¦bÃĪ«¦w©w©Ê¤Î±M§Q¦³¬ð¯}«á¡A¶i¤J¤T´ÁÁ{§É¸ÕÅç¡C

6.¦]À³±¹¬I:µL¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)­««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡A¹w­p©MÃøªv«¬­««×¼~Æ{¯g(SNA1)¤@¨Ö±Ò°Ê¦¬®×¡C

(2)SNG12 ­ì®ÆÃĬ°¥Ò°ò¥Ì®ò»Ä¦@´¹¡A¬O¥Ì®ò»Ä¦^¦¬§í¨î¾÷¨îªº·s¾÷Âà·sÃÄ¡A¬ü°ê­¹«~ÃĪ«ºÞ²z§½(FDA)½T»{¬°¡u·s¤Æ¾Ç¤À¤l¡v¡]New Chemical Entity¡^¨Ã¤wÀò±o¬ü°ê±M§Q¡C¤T´Á¸ÕÅ禳¨â¤jÁ{§É®Ä¥Î«ü¼Ð¡G¤@¬°¼~Æ{¯gª¬¥t¤@¬°¦Û±þ¯gª¬¡A¥Ø«e¦Û±þ¯gª¬¨ÃµLÃĪ«ªvÀø¡C¥H¥xÆW¬°¨Ò¡A¨C¤Ñ¬ù¤Q¤H¦Û±þ¨­¤`¡A¨ä¤¤µ´¤j³¡¤À¿©¦³­««×¼~Æ{¯g¡C

(3)·sÃĶ}µo¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥§ë¸ê­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_¡C

50»õ¬üª÷ªº¥«³õ!!

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/23 ¤U¤È 05:16:24²Ä844½g¦^À³
Amos¤j...

±z¯uªº·Q¤Ó¦h¤F..¿³ÂdªÑ²¼¬O¥H·í¤é§¡»ù§@¬°¹j¤é¶}½L»ù..¹sªÑ®Ú¥»¼vÅT¤£¤FªÑ»ù...

§Ú­Ì¤£·|¦]¬°·í¤éªº¹sªÑ¶R©Î½æªº»ù®æ¦Ó¦³«ùªÑ¤Wªºªi°Ê...

¤ß®®ª©¤W·|¶Rªº¥H±M·~¤á.¤¤¹ê¤á©M¤j¤á§ë¸êªÌ..¥Hªø½u§ë¸êªÌ©~¦h...

¬Ýªº¬O¤½¥qªºÆF»î¤Hª«/¤½¥q·sÃĪº¥«³õ/¤½¥q·sÃĪº¦¨¥\²v...

§Ú­Ì¬Ýªº¬O¤½¥qªº¥¼¨Ó©Ê...

¤j®aªºµo¤å..¬O¥H¤½¥q·sÃĬÛÃö¸ê°T°Q½×¬°¥D...

¥H¤W~~¨Ñµ½¨}.´¼¼zªº¾Ô¤Í­Ì°Ñ¦Ò~~

·|­û:²q·Q10136148µoªí®É¶¡:2018/5/23 ¤U¤È 04:55:50²Ä843½g¦^À³
¬Q¤Ñ¤½¥qªº¤½§i

­««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡A¹w­p©MÃøªv«¬­««×¼~Æ{¯g(SNA1)¤@¨Ö±Ò°Ê¦¬®×

¨º¬O§_2016 FDA®Ö­ãªºADÁ{§É¸ÕÅç SND-14 , ¤]±N©M SND-51 ¤@¨Ö±Ò°Ê¦¬®× ?

¿D¬w¾ÇªÌªº¬ã¨s

Molecular Targets of Tannic Acid in Alzheimer¡¦s Disease.

www.ncbi.nlm.nih.gov/pubmed/28176625

Abstract

Tannic acid (TA)has strong antioxidant/free radical scavenging, antiinflammatory, anti-viral/bacterial, and anti-carcinogenic properties.

TA¨ã¦³±j§Ü®ñ¤Æ¾¯/¦Û¥Ñ°ò²M°£¡A§Üª¢¡A§Ü¯f¬r/²Óµß©M§Ü­PÀù©Ê

The neuroprotective effects of TA against AD have been shown in several in vitro and in vivo models of AD.

Apart from its potent antioxidant and anti-inflammatory roles, evidence suggests that TA is also a natural inhibitor of £]-secretase (BACE1) activity and protein expression.

BACE1 is the primary enzyme responsible for the production and deposition of A£] peptide.

TA also destabilises neurotoxic amyloid beta (A£]) fibrils in vitro.

Apart from its effects on the A£] cascade, TA can also inhibit the in vitro aggregation of tau peptide, a core component of intracellular neurofibrillary tangles (NFTs).

This review summarizes the relevance of TA and TA-related vegetable extracts (tannins) in the pathogenesis of AD and its enzymatic targets.

It also highlights the significance of TA as an important lead compound against AD.

¥t¥~, SNG-12 ª½§ð¤T´Á ©Î³\¤]¥NªíµÛ¤½¥qªº«H¤ß( ? or ! )

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/23 ¤U¤È 01:56:12²Ä842½g¦^À³
¤j¤á¤H®a...

³o°ÝÃD..±M·~ªº¦Ñ¥v¤j¤j©ó2¤ë¥÷¦³Á|¨Ò»¡©ú¦p¤U...°µ¤F¤T´Á¤~¥h¥Ó½ÐBTD¬O¥i¥Hªº

·|­û¡G¦Ñ¥v10140531 µoªí®É¶¡:2018/2/6 ¤U¤È 11:05:44²Ä 286 ½g¦^À³

¤@¯ë»¡¨Ó¡AFDA§Æ±æ¥Ó½ÐBTDªº®É¶¡¤£­n±ß©óEOP2¡A­è­èZogenix«Å¥¬¥L­Ì®aªº§C¾¯¶q´îªÎÃÄÀò±oDravet SyndromeªºBTD¡A®Ú¾Úªº«o¬O¤T´ÁÁ{§Éµ²ªG¡¨ the results from Study 1, Zogenix¡¦s first global Phase 3 trial of ZX008¡¨¡A¤]´N¬O»¡°µ¤F¤T´Á¤~¥h¥Ó½ÐBTD¬O¥i¥Hªº¡A·s»D½Z³sµ²¦p¤U

zogenixinc.gcs-web.com/news-releases/news-release-details/zogenix-announces-receipt-fda-breakthrough-therapy-designation¡A

³o­ÓÁ{§É¼Æ¾Ú³y¦¨¥h¦~9/29³æ¤é¼Éº¦172%¡A¥«­È½Ä¤W12»õ¬üª÷¡A¥ú¨~¤@«×À£¹LGW¡C

·|­û:¤j¤á¤H®a10140174µoªí®É¶¡:2018/5/23 ¤U¤È 01:45:15²Ä841½g¦^À³
½Ð°Ý¦U¦ì±M®a,SNG12¶i¤J¤T´ÁÁ{§É,­ì¥»¹w´Á¦³¥i¯à·|®³¨ìBTD, ³o¼Ë¬O¤£¬O´N¨S§Æ±æ¤F?
·|­û:º©¹CªÌ10144096µoªí®É¶¡:2018/5/23 ¤U¤È 01:33:30²Ä840½g¦^À³
Amos¥S,

§Ú¤£À´­n©È¤°»ò¡H¥i§_¶}ÄÀ¤@¤U

­º¥ý¿³Âd¶}½L»ùªººâªk¬O«e¤@¤é¦¨¥æ§¡»ù¡A¤]´N¬O»¡¥Î1ªÑ10ªÑ©Ô¦A°ª¡A²Ä¤G¤Ñ§¡»ù´N¥´¦^­ì§Î

¦A¨Ó¿³Âd¬O¤H¤u·b¦X¡A²{»ù¦Aº}«G¹ê»Ú¦¨¥æ´N¬O¤£¤@¼Ë¡A¨S¦³¹ê»Ú¶R½Lªº¸Ü¡A³oºØ1ªÑ10ªÑ¬O¶R¤£¤W¥hªº

·|­û:·Q·Q10140340µoªí®É¶¡:2018/5/23 ¤W¤È 11:34:51²Ä839½g¦^À³
¤p§Ì¦³®É­Ô´N³o¼Ë¤l¶R°Ú...

¤Ï¥¿­n¶R, ¦³®É­Ô¶R¤@¨â±i, ¦³®É­Ô¶R1ªÑ, ¦³®É­Ô¶R10ªÑ,100ªÑ

³o´N¹³¹sªÑ¥æ©ö...¤j¤j¤£¥ÎÅå³Y¤Ó¦h¤~¬O...

¸Ü»¡SNG 12¬ðµMÃz½Ä¨ìÁ{§É¤T´Á, ³o¥Nªí¬Æ»ò?

¾÷Âà³QFDA±j¯P»{¥i? ÂåÀø¥¼³Qº¡¨¬ªº¯f¼x³QFDA±j¤O±ÀÂË? ³]­p¨}¦nªºP3Á{§É´ú¸Õ ?

¯uªº¬Oªí¥Ü¤ß®®¦³»{¯u¦b°µ¨Æ.

¤£¦Ppipeline¤@ª½¦b³W¹º¤¤ ·Pı¦h±m¦h«º¤F°_¨Ó...

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/23 ¤W¤È 10:15:51²Ä838½g¦^À³
¼~Æ{¯g¥«³õ¨C¦~¥þ²y³W¼Ò¦h¤j...

®Ú¾Ú¥xÆW¸gÀÙ¬ã¨s°|¥Íª«¬ì§Þ²£·~¬ã¨s¤¤¤ßªº±À¦ô¡A

2015 ¦~¥þ²y§Ü¼~Æ{²£«~¥«³õ³W¼Ò¬° 87 »õ¬ü¤¸¡A

2020 ¦~±N¹F 93 »õ¬ü¤¸¡A

2015 ¦~∼2020 ¦~ªº¦~½Æ¦X¦¨ªø²v (CAGR) ¬° 1.25¢H¡C

¨º»ò¤ß®®ªº¦X²zNPV¬O¦h¤Ö...ª©¤W¦p¦³§ë¬ã³¡ªº¤j¤j...¥i®Öºâ¤@¤U...

¦b»ù­È»·»·§C¦ô®É...»°§Ö¶R¶iªø´Á«ù¦³§a...

¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò

·|­û:´M³V10132258µoªí®É¶¡:2018/5/23 ¤W¤È 09:31:33²Ä837½g¦^À³
¬Ý¨Ó«á­±ÁÙ¦³¶i®iÁÙ¦³SND13

~­n¾Ç²ß«e½ú!

Åý¤l¼u­¸¤@·|!

¤£«æµÛ¥X³õ!³£µ¥¨º»ò¤[¤F~

·|­û:¤p©ú10146339µoªí®É¶¡:2018/5/22 ¤U¤È 09:46:58²Ä836½g¦^À³
¤ß®®µo¥¬­«°T®@¡I

¥»¤½¥q¬ãµo¤¤­««×¼~Æ{¯g¤§¼~Æ{¤Î¦Û±þ¯gª¬(SNG12)¡A Àò±o¬ü°ê­¹«~ÃĪ«ºÞ²z§½(FDA)®Ö­ã°õ¦æ¤HÅéÁ{§É²Ä¤T´Á¸ÕÅç

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/21 ¤W¤È 10:13:47²Ä835½g¦^À³
²q·Q¤j~~~

ÁÂÁ¤@°_¤À¨É¤µ¦~·sÃĬì§Þ¦~·|ªº¸ê°T....

§Ú­Ì¬Ý¨ì..

½²±Ð±ÂºaÀò¥»¦~«×·sÃĬì§Þ¦~CNS»â°ìªº¥D«ù¤H...

³ø§i¦w±Æ«e¬q..²Ä¤G³õ...

¥DÃD:Facilitating NMDA System Balance to Address CNS Disorders

¥ú¬Ý³ø§i¥DÃD...«P¶iNMDA¨t²Î¥­¿Å¸Ñ¨MCNS¯e¯f...¤µ¦~«×ªº³ø§iºë±m¥i´Á...

¥H¤W~~¨Ñµ½¨}.´¼¼zªºªø´Á§ë¸ê¾Ô¤Í­Ì°Ñ¦Ò~~

·|­û:²q·Q10136148µoªí®É¶¡:2018/5/20 ¤W¤È 09:54:26²Ä834½g¦^À³
´X¤Ñ«e

¤p©¯¹B¤j¤¶²Ðªº

BIT¡¦s 16th Annual Congress of International Drug Discovery Science and Technology-2018

Theme: Rethinking the Next Big Things in Pharma Innovations

Time: August 16-19, 2018

Place: Boston Marriott Cambridge, USA

www.iddst.com/iddst2018/ScientificProgram3_5.asp

¨ä¤¤ CNS »â°ì

Session 3704: CNS and Neurodegenerative Disorders Drugs and Therapies

Day 3: Afternoon, Saturday, August 18, 2018

13:30-16:20

Chair: Dr. Guochuan E Tsai, CEO, SyneuRx Neuroscience; Professor-in-Residence, David Geffen School of Medicine, University of California at Los Angeles, USA

½²±Ð±ÂÁ¿ÃD

14:00-14:25

Title:

Facilitating NMDA System Balance to Address CNS Disorders

Dr. Guochuan E Tsai, CEO, SyneuRx Neuroscience; Professor-in-Residence, David Geffen School of Medicine, University of California at Los Angeles, USA

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/5/17 ¤U¤È 05:55:09²Ä833½g¦^À³
ÁÂÁÂ

¤p©¯¹B¤j

bio man ¤j

booli ¤j

ªº¤À¨É

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/17 ¤U¤È 02:16:14²Ä832½g¦^À³
¤À¨É¸ê°T~~

«Xù´µºë¯«¯f¾Ç®aVitaly Leonidovich MinutkoÂå¾Ç³Õ¤h...

(ºë¯«¯f¾Ç¤u§@¸gÅç¶W¹L35¦~.µÛ¦³7¥»¸Ô²Óªº±MµÛ.«X°êª¾¦Wªººë¯«¬ì¾Ç±M®a)

Vitaly Leonidovich¦b©P¤@14/05/2018 - 22:20¤À¨ÉªºªvÀøºë¯«¤Àµõ¯gªº·s¤èªk¤å³¹¤¤...

¤å¤¤´£¨ì¤j¦h¼Æ·sªº§Üºë¯«¯fÃĪ«±N©ó2019¦~¤W¥«¡C

¤å³¹³Ì«á¤]´£¨ìNaBen¡]­f¥Ò»Ä¶u¡ASyneuRx°ê»Ú[¥xÆW]¤½¥q¡^¬OD-®ò°ò»Ä®ñ¤Æ酶ªº§í»s¾¯¡A

¨Ã¥B³Q´£Ä³¥Î©óªvÀøºë¯«¤Àµõ¯g¡C

°Ñ¦Ò¨Ó·½ºô§}minutkoclinic.com/blog-doktora-minutko

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/14 ¤W¤È 09:17:10²Ä831½g¦^À³
2018¦~«×.²Ä¤Q¤»届°ê»Ú·sÃĵo©ú¬ì§Þ¦~·|...

¥Ø«e¤w¤½¥¬20¦ì°ê»Ú·sÃĦ~·|ªº³ø§i¤H...

¤ß®® Dr. Guochuan E Tsai, CEO, SyneuRx Neuroscience¤w©ó³ø§i¤H¤§¤¤...

¥ú¬Ý·sÃĦ~«×³Ì­«­n·|ijÁܽЪº³ø§i¤H...¦U¦U¨ÓÀY¤£¤p...

¤ß®®½²±Ð±Â¦C©ó­º§å·sÃÄ·|ijªº³ø§iªÌ¤¤...³o·N¸q¬O¤°»ò?¤j®a¥i¥H¦n¦n·Q·Q~~

时间¡G2018/08/16-2018/08/18

¦a点¡G剑桥ªi¤h顿ÉE»¨°s©±

¦a区¡G ¬ü国

¥D办单¦ì¡G¦Ê奥®õ国际会议¶°团

¤@¡B会议°ò¥»«H®§

1¡B²Ä¤Q¤»届国际·s药发©ú¬ì§Þ¦~会

2¡B时间¡G2018¦~8¤ë16-18¤é

3¡B¦a点¡G剑桥ªi¤h顿ÉE»¨°s©±

4¡B规¼Ò¡G500+参会规¼Ò

5¡B语¨¥¡G­^¤å

6¡B参ÉO¤è¦¡¡Gºt讲¡B参会¡B参®i¡B赞§U¡B¦X§@

7¡BÊI§}¡Gwww.iddst.com/IDDST2018/cn

¤G¡B¤j会¤¶绍

¥Ñª¾¦W国际会议¤½¥q¦Ê奥®õ国际会议¶°团¥D办ªº²Ä¤Q¤»届国际·s药发©ú¬ì§Þ¦~会¡]IDDST-2018¡^将¤_2018¦~8¤ë16-18¤é¦b¬ü国ªi¤h顿¥l开¡C

国际·s药发©ú¬ì§Þ¦~会2003¦~¥Ñ¦Ê奥®õ国际会议¶°团发°_¡A­P¤O¤_为¥þ²y药ª«¬ã发领°ìªº¬ì学®a©M¥ø业®a·f«Ø¤@个¬Û¤¬¥æ¬yÉO¦X§@ªº国际¥­¥x¡A为¦æ业发®i´£¨Ñ·s«ä¸ô¡B«ü¤Þ·s¤è¦V¡A¥H¦¹±À动¥þ²y药ª«¬ã发ªº进®i¡C国际·s药发©ú¬ì§Þ¦~会¤w经¦b¥_¨Ê¡B«n¨Ê¡B²`¦`¡B¤j¨Áµ¥¦a¦¨¥\举办¤F¤Q¤­届¡A¦¨¥\¦a§l¤Þ¤F¹OÉE¦W¥@¬ÉµÛ¦W专®a¡B学ªÌ¡B¥@¬É500üL¨î药¥ø业°ªºÞ¡B创·s«¬¨î药¥ø业®a参ÉO¡A¬O·s药¬ã发领°ì­«­nªº«~µP©Ê会议¡C

¥»届¦~会¦@设¸m¤F26场专业§Þ术论坛¡A¥D­n¥]¬A¡G药ª«¬ã发ªº³Ì·s进®i¡A¥Î¤_药ª«¬ã发ªº³Ì·s§Þ术¡A药²z¤ô¥­¤Wªº药ª«发现¡A计ºâÉó辅§Uªº药ª«发现¡A¹v¦V药ª«¡A·s«¬¤p¤À¤l§í¨î剂©M¿E动剂¡A¥Íª«ªv疗领°ì·s进®i¡A药ª«递°eªº¬ì学ÉO§Þ术¡A针对¥D­n¯e¯fªº药ª«¬ã发·s进®iµ¥¡C¦¹¥~¡A还将举办¤¤¬ü¥ø业®a°ª®p论坛¡A¥Íª«医药°ªºÝ¤H¤~©M项¥Ø对±µ会¡Bû\区©Û°Ó±À¤¶会¡B¤H¤~©Û¸u会¡Bªi¤h顿¥Íª«医药产业û\区¤Îª¾¦WÉóÌۦҹ°Ó务¬¡动¡C

¥»届¦~会将ÁÜ请¥@¬É500üL¨î药¥ø业°ªºÞ¡B国际µÛ¦W专®a学ªÌ¡B¬ü国国内¬Û关ÉóÌÛ¥Nªí¡Bª¾¦W¥ø业®aµ¥领衔¥D讲¡A¦@计200个报§i¡C将ÁÜ请来¦Û¥@¬É40¦h个国®a©M¦a区ªº¤W¤d¦ì药ª«¬ã发领°ìªº¬Û关专业¤H¤h参¥[会议¡A50®aµÛ¦W¥ø业参¥[®i览¡A将¦V¥@¬É®i¥Ü­«¤j·s药创¨îªº«eªu§Þ术©M¬ì§Þ¦¨ªG¡A¤Þ导国际·s药¬ã发领°ìªº发®i趋势©M«eªu动¦V¡A«P进¬ì¬ã¦¨ªG产业¤Æ¦X§@¡C

§Ú们诚挚¦aÁÜ请¬Û关领°ìªº专®a学ªÌ©M¥ø业¥Nªí参会参®i¡AÉO国内¥~¦P¦æ¬Û¤¬学习¥æ¬y¡B¦@¦P¦X§@¡I

¤T¡B¥D­n¬¡动

1. ²Ä¤Q¤»届国际·s药发©ú¬ì§Þ¦~会¤j会开¹õ¦¡º[¥þÊ^论坛

2. ªñ30场¥­¦æªº¬ì§Þ论坛

3. ¦æ业专®a欢ªï±ß®bÉO艺术ªíºt

4. ²Ä¤Q¤»届国际·s药发©ú¬ì§Þ¦~会¤j会闭¹õ¦¡

5. ¥þ¥@¬ÉµÛ¦Wªº¥Íª«医药°ò¦aªi¤h顿¤@¤é´å

6. ¥ø业ÉO学术®ü报®i¥Ü

7. ¨î药产«~¡B§Þ术¡BªA务¥ø业®i览¬¢谈

¥|¡B³¡¤À报§i¤H¡]±Æ¦W¤£¤À¥ý¦Z¡^

Dr. Mostafa A El-S

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/11 ¤W¤È 11:26:49²Ä830½g¦^À³
²q·Q¤j~~~

¦p¬Q¤é±z´£¨ìªº¨£¸Ñ..+1...

<<¬O¶¥¹ï©Ê¥ô°È§¹¦¨ , Âà¥ô°ê»Úµ¦²¤µo®iÅU°Ý , ±N¦ì¤lÅýµ¹¤½¥q¤U¶¥¬qµo®i¥D¶bªº±M·~¤H¤~?

¥B¤U¤@­Ó¬£¥ôSyneuRx International Corp.ªºªk¤H¸³¨Æ¥Nªí¤H , ·|¤]¬O¤ß®®ªº°õ¦æ°ÆÁ`¶Ü? >>

·|­û:²q·Q10136148µoªí®É¶¡:2018/5/11 ¤W¤È 09:52:16²Ä829½g¦^À³
µo¨¥®É¶¡ 107/05/10 17:15:10

¤½§i¥»¤½¥qªk¤H¸³¨Æ¥Nªí¤H§ï¬£¤Î²Ö­p¤T¤À¤@¥H¤W¸³¨Æµo¥ÍÅÜ°Ê

1.µo¥ÍÅܰʤé´Á:107/05/10

2.ªk¤H¦WºÙ:SyneuRx International Corp.

3.ÂÂ¥ôªÌ©m¦W¤Î²¾ú:SyneuRx International Corp. ¥Nªí¤H:§d¶®¬Â³Õ¤h¡A

¥»¤½¥q°õ¦æ°ÆÁ`

4.·s¥ôªÌ©m¦W¤Î²¾ú:SyneuRx International Corp. ¥Nªí¤H:¤ý´º¥¿¡A

¥»¤½¥q¬ãµo³¡°ÆÁ`

5.²§°Ê­ì¦]:ªk¤H¸³¨Æ§ï¬£¥Nªí¤H

6.­ì¥ô´Á¡]¨Òxx/xx/xx ~ xx/xx/xx¡^:105/06/27~108/06/26

7.·s¥ô¥Í®Ä¤é´Á:107/05/10~108/06/26

8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¦P¥ô´Á¸³¨ÆÅܰʤñ²v:7/9

·|­û:²q·Q10136148µoªí®É¶¡:2018/5/10 ¤U¤È 05:15:55²Ä828½g¦^À³
µo¨¥®É¶¡ 107/05/09 23:59:07

¤½§i¥»¤½¥qªk¤H¸³¨Æ¥Nªí¤Hº[°õ¦æ°ÆÁ`Ãã¥ô¤Î²Ö­p¤T¤À¤@¥H¤W¸³¨Æµo¥ÍÅÜ°Ê

1.µo¥ÍÅܰʤé´Á:107/05/09

2.ªk¤H¦WºÙ:SyneuRx International Corp.

3.ÂÂ¥ôªÌ©m¦W¤Î²¾ú:SyneuRx International Corp. ¥Nªí¤H:§d¶®¬Â³Õ¤h¡A

¥»¤½¥q°õ¦æ°ÆÁ`

4.·s¥ôªÌ©m¦W¤Î²¾ú:¤£¾A¥Î

5.²§°Ê­ì¦]:ªk¤H¸³¨Æ¥Nªí¤Hº[°õ¦æ°ÆÁ`Ãã¥ô¡AÂà¥ô°ê»Úµ¦²¤µo®iÅU°Ý

6.­ì¥ô´Á¡]¨Òxx/xx/xx ~ xx/xx/xx¡^:105/06/27~108/06/26

7.·s¥ô¥Í®Ä¤é´Á:NA

8.¨ä¥LÀ³±Ô©ú¨Æ¶µ:¦P¥ô´Á¸³¨ÆÅܰʤñ²v:7/9

½²±Ð±Âªº¤Ò¤H§d¶®¬Â³Õ¤h Ãã¥ôSyneuRx International Corp.ªk¤H¸³¨Æ¥Nªí¤H

º[¤ß®®°õ¦æ°ÆÁ`

³o¬O¦n®ø®§? ÁÙ¬OÃa®ø®§?

¬O¶¥¹ï©Ê¥ô°È§¹¦¨ , Âà¥ô°ê»Úµ¦²¤µo®iÅU°Ý , ±N¦ì¤lÅýµ¹¤½¥q¤U¶¥¬qµo®i¥D¶bªº±M·~¤H¤~?

¥B¤U¤@­Ó¬£¥ôSyneuRx International Corp.ªºªk¤H¸³¨Æ¥Nªí¤H , ·|¤]¬O¤ß®®ªº°õ¦æ°ÆÁ`¶Ü?

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

·|­û:²q·Q10136148µoªí®É¶¡:2018/5/8 ¤U¤È 03:27:58²Ä827½g¦^À³
ºñ¸­»sÃÄ ªñ5.46»õ¬ü¤¸ ¦¬Áʧܺ믫¯fÃĪ««ä·ç±d

¨Ó·½¡G ¦Ì¤ººô ¡@2018-05-08

med.sina.com/article_detail_100_1_45426.html

2018¦~5¤ë7¤é¡Aºñ¸­»sÃÄ(2186.HK)»PAstraZeneca­q¥ß¸ê²£¦¬Áʤγ\¥i¨óij¡A«ü©w¦a°Ï³\¥i¸ê²£³\¥iÃÒÂл\51­Ó°ê®a©M¦a°Ï¡A¥]¬A¤¤°ê¡B­^°ê¡B¤Ú¦è¡B¿D¤j§Q¨È¡B¨F¯Sªü©Ô§B¡B¾¥¦è­ô¡B«nÁú¡B®õ°ê¡Bªü®Ú§Ê¡B°¨¨Ó¦è¨È¤Î¨ä¥L¦ì©ó¨È¬w¡B©Ô¤B¬ü¬w¡B«D¬w¡B¤j¬v¬w©MªF¼Úªº°ê®a©M¦a°Ï¡CÂàÅý¸ê²£¤Î³\¥i¸ê²£¦¬ÁÊ»ù¤§Á`ª÷ÃB¬°546¦Ê¸U¬ü¤¸¡C

²£«~¸ê®Æ

«ä·ç±d(´I°¨»Ä喹²¸¥­¡B³tÄÀ¡BIR)¤Î«ä·ç±d½wÄÀ¤ù(½wÄÀ»s¾¯)¤D¨ã¦³§Ü§íÆ{¯S©Êªº«D¨å«¬§Üºë¯«¯f(AAP)ÃĪ«¡C

«ä·ç±dªº¥D­n¯f¯g¬OªvÀøºë¯«¤Àµõ¯g©MļÆ{¯g¡C«ä·ç±d½wÄÀ¤ù¦b­Y¤z¥«³õ¥çÀò­ã¥Î©ó§íÆ{¯g©M¼sªx©ÊµJ¼{¯g¡C

ºñ¸­»sÃĪí¥Ü¡A¥Ø«e¤j¶q±wªÌ¤Î¼ç¦b±wªÌ¦³¹ïºë¯«¤Àµõ©MļÆ{¯gªvÀø²£«~ªº»Ý¨D¡A±N¬°¶°¹Î§e²{­«¤jªº¥«³õ¾÷¹J¡C

·|­û:¤p©¯¹B10141538µoªí®É¶¡:2018/5/3 ¤W¤È 09:46:40²Ä826½g¦^À³
¨ÌGoodinfo¥xÆWªÑ¥«¸ê°Tºô¸ê°T...

¥~¸ê4¤ë¥÷¶R¤J¤ß®®¦@31±i...¥~¸ê¼W¥[¿³Âdªº«ùªÑ...­È±oª`·N...

·|­û:seniorbbs10144999µoªí®É¶¡:2018/5/1 ¤U¤È 05:25:53²Ä825½g¦^À³
¬ù·í²{ª÷+©w¦s ÁÙ¦³4.x»õ¤¸¡A¤µ¦~«×À³¸ÓÁÙ¼µ±o¹L¡C¡C¡C¡C¡C¡C
·|­û:²q·Q10136148µoªí®É¶¡:2018/4/30 ¤U¤È 04:33:13²Ä824½g¦^À³
¤ß®®¬ãµo¶O¥Î¤@Äý ( ¤d¤¸·s¥x¹ô )

¨Ó·½ : ¦U¦~°]³ø

104¤W¥b¦~ : 36,544

104¤U¥b¦~ : 47,693

105¤W¥b¦~ : 56,337

105¤U¥b¦~ : 68,172

106¤W¥b¦~ : 94,128

106¤U¥b¦~ : 168,063

¶È¨Ñ°Ñ¦Ò

ÁÂÁ¤j®a!

§Ú­n¦^À³¥»¸ÜÃD
·|­û:
§@ªÌ:
¬ÛÃöªÑ²¼¤½¥q¦WºÙ:¤ß®®¥ÍÂå
¤º®e:
½Ð¥ýµn¤J­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹
°Q½×°Ï¬ÛÃö³W©w¡G
1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C

¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178 ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѬÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!